Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Launched by INNOVENT BIOLOGICS (SUZHOU) CO. LTD. · May 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new drug called IBI3005 for patients with advanced solid tumors that cannot be surgically removed. The main goals are to see how safe the drug is, how well it can be tolerated, and to find out the highest dose that can be given without causing serious side effects. If you're between the ages of 65 and 74 and have already been treated with a specific type of therapy for your cancer but your disease has worsened, you might be eligible to participate. However, some health conditions, like active infections or certain heart problems, may prevent you from joining.

Participants in this trial will receive IBI3005 and will be closely monitored by the medical team to check how well they respond to the treatment and to identify any side effects. It's important to note that you cannot receive live vaccines during the trial, but you can have inactivated vaccines if needed. This is an early-phase study, meaning researchers are still learning about the drug, so your participation could help improve treatment options for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects Should have been previously treated with a third-generation EGFR TKI with disease progression. Subjects with positive other driver genes or METex14 mutations are required to undergo targeted therapy and disease progression.
• Exclusion Criteria:
• • Received live vaccines within 4 weeks prior to first administration of the study drug or plan on receiving any live vaccine during the study.Patients are allowed to receive inactivated vaccines.
• Uncontrolled diseases including:
• • Infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first dose of the study drug（ antiviral medication for hepatitis B and hepatitis C infection that are compliant with the protocol were allowed）;
• • Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
• • Acute or chronic active hepatitis B (HbsAg positive and/or HbcAb positive with HBV DNA titer ≥ 104 copies/mL or ≥ 2000 IU/mL or higher than lower limit of detection) or C (HCV Ab positive with HCV RNA titer \> 103 copies/mL or higher than lower limit of detection);
• • Active COVID-19 infection with obvious symptoms requiring treatment or hospitalization, such as pyrexia, dyspnea, nausea, vomiting, diarrhea, etc.;
• • Active tuberculosis infection, or still on anti-tuberculosis therapy or received anti tuberculosis therapy within 1 year prior to first administration of the study drug;
• • Active syphilis infection or latent syphilis requiring treatment;
• • Symptomatic congestive heart failure Grade II-IV (New York Heart Association \[NYHA\]), symptomatic or uncontrolled arrhythmias, QTc interval \> 480 ms or personal or family history of congenital long/short QT syndrome;
• • Hypertension that does not receive standardized therapy or still uncontrollable hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg); Any history of life-threatening hemorrhage, or hemorrhage requiring (including but not limited to gastrointestinal bleeding, hemoptysis, etc) blood transfusion, endoscopy, or surgery, within 3 months prior to the first administration of study drug;